tradingkey.logo

Titan Pharmaceuticals Inc

TTNP
View Detailed Chart

4.310USD

+0.130+3.11%
Close 09/19, 16:00ETQuotes delayed by 15 min
5.73MMarket Cap
LossP/E TTM

Titan Pharmaceuticals Inc

4.310

+0.130+3.11%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.11%

5 Days

+0.47%

1 Month

-15.49%

6 Months

+17.76%

Year to Date

+32.21%

1 Year

-22.48%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
249 / 506
Overall Ranking
407 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Undervalued
The company’s latest PE is -1.47, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 414.53K shares, decreasing 9.21% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 11.38K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.49.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Ticker SymbolTTNP
CompanyTitan Pharmaceuticals Inc
CEOMr. Weei Jye Chay
Websitehttps://www.titanpharm.com/
KeyAI